Eltrombopag Improves Hematopoiesis in Patients with Low to Intermediate-2 Risk Myelodysplastic Syndrome (MDS)

In conclusion, our results suggest that EPAG is well-tolerated and effective in restoring hematopoiesis in patients with low to intermediate-2 risk MDS, particular with a prior history of hypoplastic bone marrow failure syndromes. EPAG was discontinued for robust response in the majority of responders but declining blood cell counts were observed in about 50% of them. Variants in MCG were more common at study entry compared to patients with aplastic anemia (Yoshizato, NEJM, 2015). However, EPAG appears not to selectively promote expansion of clones harboring MCGs in this patient population.DisclosuresTownsley: National Institute of Health: Research Funding. Scheinberg: Pfizer: Speakers Bureau; Novartis: Consultancy, Speakers Bureau; Janssen: Honoraria, Research Funding. Dunbar: National Institute of Health: Research Funding. Young: GlaxoSmithKline: Research Funding; CRADA with Novartis: Research Funding; National Institute of Health: Research Funding. Winkler: National Institute of Health: Research Funding.

Source: Blood - November 21, 2018 Category: Hematology Authors: Vicente, A., Gutierrez-Rodrigues, F., Giudice, V., Wu, Z., Kajigaya, S., Fernandez Ibanez, M. d. P., Albitar, M., Weinstein, B., Calvo, K. R., Townsley, D. M., Scheinberg, P., Dunbar, C. E., Young, N. S., Winkler, T. Tags: 637. Myelodysplastic Syndromes-Clinical Studies: Novel Therapeutics I Source Type: research